SAGE Therapeutics (NASDAQ:SAGE) has been given a $210.00 price target by equities researchers at LADENBURG THALM/SH SH in a research report issued to clients and investors on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. LADENBURG THALM/SH SH’s price objective would suggest a potential upside of 89.79% from the stock’s current price.

Several other equities research analysts also recently issued reports on SAGE. BidaskClub raised shares of SAGE Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, December 4th. JPMorgan Chase & Co. set a $205.00 price target on shares of SAGE Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, November 6th. Cowen reaffirmed a “buy” rating and set a $207.00 price target on shares of SAGE Therapeutics in a research note on Thursday, November 1st. Oppenheimer set a $170.00 price target on shares of SAGE Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, November 20th. Finally, Canaccord Genuity set a $220.00 price objective on shares of SAGE Therapeutics and gave the stock a “buy” rating in a report on Thursday, November 1st. Two investment analysts have rated the stock with a sell rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $202.00.

SAGE Therapeutics stock opened at $110.65 on Tuesday. SAGE Therapeutics has a 12-month low of $100.16 and a 12-month high of $195.97.

SAGE Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($2.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.41) by ($0.22). During the same period in the previous year, the firm earned ($1.97) EPS. Equities research analysts forecast that SAGE Therapeutics will post -7.75 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in the business. FMR LLC grew its holdings in SAGE Therapeutics by 0.3% during the 3rd quarter. FMR LLC now owns 6,999,644 shares of the biopharmaceutical company’s stock worth $988,700,000 after acquiring an additional 22,266 shares in the last quarter. Vanguard Group Inc. grew its holdings in SAGE Therapeutics by 6.9% during the 3rd quarter. Vanguard Group Inc. now owns 4,085,812 shares of the biopharmaceutical company’s stock worth $577,121,000 after acquiring an additional 262,990 shares in the last quarter. BlackRock Inc. grew its holdings in SAGE Therapeutics by 0.9% during the 3rd quarter. BlackRock Inc. now owns 2,816,410 shares of the biopharmaceutical company’s stock worth $397,818,000 after acquiring an additional 23,862 shares in the last quarter. OppenheimerFunds Inc. grew its holdings in SAGE Therapeutics by 2.2% during the 2nd quarter. OppenheimerFunds Inc. now owns 1,598,167 shares of the biopharmaceutical company’s stock worth $250,162,000 after acquiring an additional 34,389 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in SAGE Therapeutics by 7.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,564,548 shares of the biopharmaceutical company’s stock worth $244,898,000 after acquiring an additional 110,134 shares in the last quarter.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Recommended Story: How much can an individual set aside as a catch-up contribution?

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.